Navigation Links
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Date:2/1/2010

CAMBRIDGE, Mass., Feb. 1 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study in 2010.

"We are pleased that the FDA approved the SPA agreement and are confident that we now have a clearly defined path to submission of a Biologics License Application for Vascugel," said Fred Chereau, president and chief executive officer at Pervasis. "We look forward to beginning the Phase 3 study and to confirming the safety and efficacy results from our Phase 1/2 study in a larger patient population."  

This Phase 3, single-blind, randomized, controlled, multi-center study will evaluate the efficacy and safety of Vascugel in approximately 390 patients with end-stage renal disease (ESRD) undergoing creation of an arteriovenous (AV) graft for hemodialysis access. The primary objective of this study will be to evaluate the efficacy of Vascugel in extending the duration of primary patency (lack of vessel obstruction) as compared to standard-of-care treatment.  

Under the SPA procedure, FDA formalizes its agreement that the design of the Phase 3 trial is acceptable to support a regulatory submission seeking new drug approval.

The SPA agreement follows the recent publication of positive Phase 1/2 results for Vascugel in the December issue of the Journal of Vascular Surgery (Conte et al. J Vasc Surg 2009; 50:1359-68). The study was designed to assess feasibility, safety, and preliminary effects on patency of Vascugel in patients requiring
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011 Varian Medical Systems (NYSE: VAR ... information system has received Surescripts® e-prescribing certification for new ... ARIA system to manage radiation therapy treatments will be ... the Surescripts network. "E-Prescribing allows the ...
... Mont., May 5, 2011 Bacterin International Holdings, ... a creator and developer of revolutionary bone graft material ... it is commencing distribution of the Company,s third human ... Bacterin,s hMatrix® is an acellular matrix processed ...
Cached Medicine Technology:The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 2The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 3Bacterin International Holdings Launches Third Biologic Scaffold 2Bacterin International Holdings Launches Third Biologic Scaffold 3
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... 17, 2014 Meaningful long-term survival is possible ... the abdomen when treated with cytoreductive surgery with ... first-of-its-size analysis by physicians at Wake Forest Baptist ... largest reported, single-center experience with cytoreductive surgery and ... and analysis of 20 years, worth of patient ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... other particles tracked indoors can be harmful, researchers warn , ... that coats your furniture and floors comes from outdoors and ... The researchers developed a computer model that can track the ... found that more than 60 percent of household dust originates ...
... ... featured Keynote at this year,s Molecular Medicine Tri-Conference, is the inspiration for a new ... ... 11, 2009 -- Cambridge Healthtech Institute,s (CHI) flagship event, the Molecular Medicine Tri-Conference (February ...
... WellPoint,s affiliated Life and Disability Companies are pleased to announce ... help new mothers adjust to their newborn baby and return ... available to all new and in-force short term disability plans ... have access to Newborn and Parenting Resources once their baby ...
... Internationally recognised refractive ... talk the audience through each step of the procedure as the laser treatment is being ... ... procedure in a free live broadcast. He will talk the audience through each step of ...
... ... ... HEALTHeCAREERS , North America’s premier healthcare Network, is advertising more than 14,000 job ... to be one of the few bright spots in the North American job market. ...
... Vivacare.com ... honor of Epilepsy Awareness Month. , ... Berkeley, CA (PRWEB) Nov 9, 2009 -- Vivacare provides ... in honor of Epilepsy Awareness Month. , , , , ,Leading neurologists, such as ...
Cached Medicine News:Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:WellPoint's Affiliated Life and Disability Companies Offer Newborn and Parenting Resources to Ease New Mothers' Transition Back to Work After Maternity Leave 2Health News:Eye Surgeon Broadcasts own Surgery 2Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Neurologists Receive New Patient Education Resources from Vivacare for Epilepsy Awareness Month 2
... Volk's super series ... lenses. Variable retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Volk indirect lenses. High magnification views of the posterior pole....
... This contact class is particularly ... lamps which have a smaller ... the reduction prism than the ... fundus / iridocornea. Mirror angle ...
Medicine Products: